NeurogesX, Inc. (JOBS) Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
11/17/2009 6:25:29 AM
More...
|
NeurogesX, Inc. Reports Third Quarter 2009 Results Conference Call Today at 9am ET
11/6/2009 10:54:55 AM
More...
|
NeurogesX, Inc. Expands Commercial Operations Leadership Team Adds Key Sales, Marketing and Commercial Executives in Preparation for Possible U.S. Product Launch
11/5/2009 10:58:14 AM
More...
|
NeurogesX, Inc. to Present at Two November Conferences
10/30/2009 8:59:47 AM
More...
|
NeurogesX, Inc. to Present at JMP Securities Healthcare Focus Conference
10/1/2009 10:00:53 AM
More...
|
NeurogesX, Inc. Reports Second Quarter 2009 Results Conference Call Today at 9 a.m. ET PDUFA Date Extended to November 16, 2009 for Qutenza(TM) New Drug Application in Postherpetic Neuralgia
8/7/2009 10:41:12 AM
More...
|
NeurogesX, Inc. (JOBS) Announces New PDUFA Date for Qutenza(TM) New Drug Application
8/6/2009 6:58:39 AM
More...
|
NeurogesX, Inc. (JOBS) Announces Preliminary Results of FDA-Requested Qutenza(TM) Study; PDUFA Date of August 16, 2009
7/24/2009 8:22:40 AM
More...
|
NeurogesX, Inc. Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
7/24/2009 8:15:27 AM
More...
|
NeurogesX, Inc. Announces Resignation of Bruce A. Peacock from Board of Directors Receives Nasdaq Notice Regarding Audit Committee Compliance
7/19/2009 10:53:45 PM
More...
|
|